Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:52 pm Sale |
2024-09-30 | 13G | Context Therapeutics Inc. CNTX |
Great Point Partners, LLC | 6,934,982 9.250% |
-484,373 (-6.53%) |
Filing History |
| 2024-11-14 4:47 pm Sale |
2024-09-30 | 13G | UroGen Pharma Ltd. URGN |
Great Point Partners, LLC | 758,786 1.800% |
-1,861,759 (-71.04%) |
Filing History |
| 2024-11-14 4:46 pm Sale |
2024-09-30 | 13G | Elevation Oncology, Inc. ELEV |
Great Point Partners, LLC | 0 0.000% |
-3,877,172 (Position Closed) |
Filing History |
| 2024-11-14 4:45 pm Sale |
2024-09-30 | 13G | Alpine Immune Sciences, Inc. ALPN |
Great Point Partners, LLC | 0 0.000% |
-3,703,433 (Position Closed) |
Filing History |
| 2024-08-15 4:03 pm Purchase |
2024-08-06 | 13G | Elevation Oncology, Inc. ELEV |
Great Point Partners, LLC | 3,877,172 6.560% |
3,877,172 (New Position) |
Filing History |
| 2024-08-05 4:03 pm Purchase |
2024-07-26 | 13G | ProMIS Neurosciences, Inc. PMN |
Great Point Partners, LLC | 3,005,698 9.990% |
3,005,698 (New Position) |
Filing History |
| 2024-07-18 4:10 pm Purchase |
2024-07-16 | 13G | Unicycive Therapeutics, Inc. UNCY |
Great Point Partners, LLC | 8,559,000 9.990% |
8,559,000 (New Position) |
Filing History |
| 2024-06-05 10:45 am Purchase |
2024-05-31 | 13G | Context Therapeutics Inc. CNTX |
Great Point Partners, LLC | 7,419,355 9.890% |
7,419,355 (New Position) |
Filing History |
| 2024-04-08 4:10 pm Purchase |
2024-04-01 | 13G | Outlook Therapeutics, Inc. OTLK |
Great Point Partners, LLC | 2,231,324 9.990% |
2,231,324 (New Position) |
Filing History |
| 2024-02-14 4:39 pm Unchanged |
2023-12-31 | 13G | Zura Bio Limited ZURA |
Great Point Partners, LLC | 3,295,000 7.560% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:39 pm Unchanged |
2023-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN |
Great Point Partners, LLC | 2,792,927 9.990% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:38 pm Unchanged |
2023-12-31 | 13G | UroGen Pharma Ltd. URGN |
Great Point Partners, LLC | 2,620,545 8.490% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:38 pm Purchase |
2023-12-31 | 13G | OptiNose, Inc. OPTN |
Great Point Partners, LLC | 765,608 9.990% |
11,293 (+1.50%) |
Filing History |
| 2024-02-14 4:37 pm Purchase |
2023-12-31 | 13G | Neurogene Inc. NGNE |
Great Point Partners, LLC | 994,229 7.750% |
25,000 (+2.58%) |
Filing History |
| 2024-02-14 4:37 pm Sale |
2023-12-31 | 13G | Heron Therapeutics, Inc. HRTX |
Great Point Partners, LLC | 0 0.000% |
-6,360,161 (Position Closed) |
Filing History |
| 2024-02-14 4:37 pm Sale |
2023-12-31 | 13G | Precision BioSciences, Inc. DTIL |
Great Point Partners, LLC | 0 0.000% |
-269,993 (Position Closed) |
Filing History |
| 2024-02-14 4:36 pm Purchase |
2023-12-31 | 13G | Avalo Therapeutics, Inc. AVTX |
Great Point Partners, LLC | 2,085 0.260% |
2,085 (New Position) |
Filing History |
| 2024-02-14 4:36 pm Purchase |
2023-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN |
Great Point Partners, LLC | 3,703,433 6.370% |
65,715 (+1.81%) |
Filing History |
| 2023-12-27 4:03 pm Purchase |
2023-12-18 | 13G | Neurogene Inc. NGNE |
Great Point Partners, LLC | 969,229 7.560% |
969,229 (New Position) |
Filing History |
| 2023-10-12 4:04 pm Purchase |
2023-10-02 | 13G | VistaGen Therapeutics, Inc. VTGN |
Great Point Partners, LLC | 2,792,927 9.990% |
2,792,927 (New Position) |
Filing History |